-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Due to the change of lifestyle and the acceleration of the aging process, the number of patients with type 2 diabetes in the world is increasing, and the corresponding therapeutic drug field has also become a huge market.
The GLP-1RA dispute between Eli Lilly and Novo Nordisk
The GLP-1RA dispute between Eli Lilly and Novo NordiskThe main competitors in the field of GLP-1 receptor agonists are Eli Lilly and Novo Nordisk.
®
GLP-1 drug sales
Eli Lilly’s next type 2 diabetes pipeline's blockbuster product will be Tirzepatide, which has now issued a strong challenge to semaglutide.
On March 4, 2021, Eli Lilly's Phase III clinical Tizepatide and Semaglutide head-to-head comparison of SURPASS-2 was successful.
SURPASS-2 test results
All three test doses of Tirzepatide can significantly reduce blood sugar levels and body weight.
When diabetes drugs are not just for diabetes
When diabetes drugs are not just for diabetesNovo Nordisk's main income comes from insulin, including quick-acting, long-acting and pre-mixed drugs, followed by GLP-1 drugs, but insulin sales have declined, partly because of the price drop and the new US legislation forcing the company to pay for medical insurance.
Somaglutide is considered to be the strongest GLP-1RA, and Novo Nordisk will further explore its greater potential.
Novo Nordisk's GLP-1 drug development plan
Novo Nordisk's GLP-1 drug development planIn addition, in the field of diabetes, PIONEER series of trials will continue, among which PIONEER Plus explores high-dose semaglutide 25mg and 50mgQD, SUSTAIN FORTE explores high-dose semaglutide injection 2mg QW, and also launched FOCUS The effect of marutide subcutaneous injection on diabetic retinopathy in T2D patients.
Relevant indications are also being explored drastically, and large-scale clinical trials are carried out for patients with diabetes and other diseases, including type 2 diabetes patients with cardiovascular events or chronic kidney disease, and a large-scale SOUL enrolling nearly 10,000 people is carried out.
For other non-diabetic diseases, the SELECT trial includes non-diabetic obese patients, a phase III trial for early Alzheimer's patients will also start, and the NASH trial is expected to start in 2021.
Leave and expand
Leave and expandSanofi announced in December 2019 that after the new CEO took office, it would stop research on new diabetes and cardiovascular drugs and turn to the fields of autoimmunity and oncology.
2020 sales of major products in the field of type 2 diabetes
It can be seen from the sales list that in addition to GLP-1 drugs, the sales of two SGLT-2 inhibitors have increased greatly, thanks to the expansion of the two in heart failure indications.
